Validation of risk assessment scores in predicting venous thromboembolism in patients with lung cancer receiving immune checkpoint inhibitors.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100968563 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2466 (Electronic) Linking ISSN: 14712466 NLM ISO Abbreviation: BMC Pulm Med Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001]-
    • Subject Terms:
      Venous Thromboembolism*/epidemiology ; Venous Thromboembolism*/chemically induced ; Lung Neoplasms*/drug therapy ; Immune Checkpoint Inhibitors*/adverse effects ; Immune Checkpoint Inhibitors*/therapeutic use; Humans ; Male ; Female ; Middle Aged ; Retrospective Studies ; Aged ; Risk Assessment ; ROC Curve ; China/epidemiology ; Risk Factors ; Incidence
    • Abstract:
      Introduction: Several risk scores have been proposed to predict venous thromboembolism (VTE) in hospitalized patients. However, their predictive performances in lung cancer patients receiving immune checkpoint inhibitors (ICIs) is unclear. We aimed to validate and compare their performances of the Caprini, Padua and Khorana risk scores in lung cancer patients receiving ICIs.
      Methods: This was a retrospective cohort study of patients with lung cancer treated with ICIs at West China Hospital between January 2018 and March 2022. The primary outcome was VTE during 12 months of follow-up from the first day of treatment with ICIs. The predictive performances of risk scores was determined using receiver operating characteristic (ROC) curve analysis.
      Results: Among the 1115 eligible patients with lung cancer who received ICIs, 105 patients (9.4%) experienced VTE during the 12-month follow-up period. There was a statistically significant difference in the cumulative incidence of VTE between the different risk levels as determined by Caprini and Padua scores (all P < 0.001). However, no significant difference was observed for the Khorana score (P = 0.488). The Caprini and Padua scores demonstrated good discriminative performances (AUC 0.743, 95% CI 0.688-0.799 for Caprini score; AUC 0.745, 95% CI 0.687-0.803 for Padua score), which were significantly better than that of the Khorana score (AUC 0.553, 95% CI, 0.493-0.613) (P < 0.05).
      Conclusion: In our study, the Caprini and Padua risk scores had better discriminative ability than the Khorana score to identify lung cancer patients treated with ICIs who were at high risk of VTE.
      (© 2024. The Author(s).)
    • References:
      J Immunother Cancer. 2021 Jan;9(1):. (PMID: 33436486)
      Ann Thorac Surg. 2018 Mar;105(3):879-885. (PMID: 29397103)
      Dis Mon. 2005 Feb-Mar;51(2-3):70-8. (PMID: 15900257)
      Am J Med. 2016 May;129(5):528-535. (PMID: 26551977)
      J Natl Compr Canc Netw. 2022 Jun 21;20(13):. (PMID: 35728777)
      J Thromb Haemost. 2020 Aug;18(8):1940-1951. (PMID: 32336010)
      Thromb Res. 2012 Nov;130(5):735-40. (PMID: 22909830)
      Blood. 2021 Mar 25;137(12):1669-1678. (PMID: 33067632)
      Cancer Cell Int. 2023 Mar 5;23(1):40. (PMID: 36872336)
      Cancer. 2005 Dec 15;104(12):2822-9. (PMID: 16284987)
      N Engl J Med. 2015 Jul 9;373(2):123-35. (PMID: 26028407)
      J Thorac Cardiovasc Surg. 2016 Jan;151(1):37-44.e1. (PMID: 26386868)
      Blood. 2008 May 15;111(10):4902-7. (PMID: 18216292)
      Lancet. 2016 Apr 9;387(10027):1540-1550. (PMID: 26712084)
      Circulation. 2003 Jun 17;107(23 Suppl 1):I17-21. (PMID: 12814981)
      Semin Thromb Hemost. 1991;17 Suppl 3:304-12. (PMID: 1754886)
      Nat Rev Immunol. 2013 Jan;13(1):34-45. (PMID: 23222502)
      Eur J Cancer. 2021 Oct 15;158:99-110. (PMID: 34662835)
      Cancer Lett. 2016 Nov 28;382(2):240-244. (PMID: 27666776)
      J Immunother Cancer. 2023 Jan;11(1):. (PMID: 36657815)
      Chest. 2012 Feb;141(2 Suppl):e195S-e226S. (PMID: 22315261)
      J Thromb Haemost. 2010 Nov;8(11):2450-7. (PMID: 20738765)
      J Clin Oncol. 2020 Feb 10;38(5):496-520. (PMID: 31381464)
      J Thromb Haemost. 2021 May;19(5):1250-1258. (PMID: 33605020)
      JAMA Surg. 2015 Oct;150(10):941-8. (PMID: 26288124)
      CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
      J Atheroscler Thromb. 2018 Nov 1;25(11):1091-1104. (PMID: 29540637)
      Am J Med. 2016 Sep;129(9):1001.e9-1001.e18. (PMID: 27107925)
      J Thromb Haemost. 2016 Sep;14(9):1773-8. (PMID: 27273134)
      J Thromb Thrombolysis. 2022 Aug;54(2):287-294. (PMID: 35396660)
      J Thromb Haemost. 2003 Jul;1(7):1343-8. (PMID: 12871267)
      Lancet. 2017 Jan 21;389(10066):255-265. (PMID: 27979383)
      J Thromb Haemost. 2020 Jun;18(6):1398-1407. (PMID: 32168402)
      N Engl J Med. 2015 Oct 22;373(17):1627-39. (PMID: 26412456)
      Thromb Res. 2023 Jan;221:164-172. (PMID: 36396518)
      Thromb Res. 2021 Dec;208:71-78. (PMID: 34742139)
      Int J Clin Oncol. 2023 Jan;28(1):69-78. (PMID: 36357710)
      Thromb Res. 2000 Jan 1;97(1):V49-62. (PMID: 10668808)
      J Vasc Surg Venous Lymphat Disord. 2021 Sep;9(5):1151-1158. (PMID: 33383236)
      Blood. 2015 Jul 30;126(5):582-8. (PMID: 26109205)
    • Grant Information:
      355 82173182 National Natural Science Foundation of China; 2023NSFSC1939 Sichuan Science and Technology Program
    • Contributed Indexing:
      Keywords: Immune checkpoint inhibitors; Lung cancer; Risk assessment scores; Venous thromboembolism
    • Accession Number:
      0 (Immune Checkpoint Inhibitors)
    • Publication Date:
      Date Created: 20241010 Date Completed: 20241011 Latest Revision: 20241013
    • Publication Date:
      20241013
    • Accession Number:
      PMC11468413
    • Accession Number:
      10.1186/s12890-024-03323-z
    • Accession Number:
      39390440